Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...
Gilead is making a move in the hunt for antibody-drug conjugates (ADCs) that target solid tumors by tapping Tubulis, a German biotech that specializes in the molecules, to collaboratively discover and ...
Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent ...
Despite markedly slower cell therapy growth from the third to the fourth quarter of 2023—and a recent setback for Trodelvy—historically HIV-focused Gilead Sciences is not discouraged amid its oncology ...
H ulu has released a first look at its The Handmaid's Tale sequel, which will return to Gilead with a "new generation of young women" at the forefront. Titled The Testaments and based on Margaret ...
Gilead Sciences has outgrown its valuation, making it a poor investment at current levels. We previously recommended HOLD, but recent earnings have led us to a SELL recommendation. The company's ...
Company, presented a new analysis demonstrating that second-line Yescarta therapy offers consistent benefits in patients ...
FOSTER CITY, Calif. & BURLINGAME, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback